AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a Phase III study titled A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function. The study aims to assess the effectiveness of a combination of balcinrenone and dapagliflozin in reducing heart failure events and cardiovascular deaths in patients with chronic heart failure and impaired kidney function.
The study tests two experimental interventions: balcinrenone/dapagliflozin at doses of 15 mg/10 mg and 40 mg/10 mg, compared to dapagliflozin alone at 10 mg. These drugs are intended to improve cardiovascular outcomes in patients with heart failure and impaired kidney function.
This international, multi-centre study is randomized, double-blind, and uses a parallel-group design. It employs quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary purpose is treatment-focused.
The study began on February 6, 2024, with an anticipated primary completion date yet to be announced. The latest update was submitted on August 28, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
The outcome of this study could significantly influence AstraZeneca’s stock performance, as positive results might enhance investor confidence and market position against competitors in the cardiovascular treatment space. The ongoing recruitment and updates indicate continued interest and investment in this area.
The study is currently recruiting, with further details available on the ClinicalTrials portal.